Publicacións nas que colabora con David García Dorado (22)

2021

  1. Changes in the diagnosis and management of acute aortic syndrome and associated mortality in the last 20 years

    Revista Espanola de Cardiologia, Vol. 74, Núm. 3, pp. 257-262

  2. Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol

    Journal of the American College of Cardiology, Vol. 78, Núm. 5, pp. 421-433

  3. Persistent pulmonary hypertension in corrected valvular heart disease: Hemodynamic insights and long-term survival

    Journal of the American Heart Association, Vol. 10, Núm. 2, pp. 1-21

2019

  1. Clinical presentation, aetiology and outcome of infective endocarditis. Results of the ESC-EORP EURO-ENDO (European infective endocarditis) registry: A prospective cohort study

    European Heart Journal, Vol. 40, Núm. 39, pp. 3222-3232B

  2. Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial

    The Lancet Diabetes and Endocrinology, Vol. 7, Núm. 8, pp. 618-628

  3. Familial clustering of bicuspid aortic valve and its relationship with aortic dilation in first-degree relatives

    Heart, Vol. 105, Núm. 8, pp. 603-608

  4. The ESC-EORP EURO-ENDO (European Infective Endocarditis) registry

    European Heart Journal - Quality of Care and Clinical Outcomes, Vol. 5, Núm. 3, pp. 202-207

2018

  1. Alirocumab and cardiovascular outcomes after acute coronary syndrome

    New England Journal of Medicine, Vol. 379, Núm. 22, pp. 2097-2107

  2. Anatomical and clinical predictors of valve dysfunction and aortic dilation in bicuspid aortic valve disease

    Heart, Vol. 104, Núm. 7, pp. 566-573

2016

  1. Acute Arterial Hypertension in Acute Pulmonary Edema: Mostly a Trigger or an Associated Phenomenon?

    Canadian Journal of Cardiology, Vol. 32, Núm. 10, pp. 1214-1220

2011

  1. Severe thrombocytopenia complicating giant left atrial rhabdomyosarcoma

    International Journal of Cardiology, Vol. 150, Núm. 1

2010

  1. Background, incidence, and predictors of antiplatelet therapy discontinuation during the first year after drug-eluting stent implantation

    Circulation, Vol. 122, Núm. 10, pp. 1017-1025

  2. Do GRACE (Global Registry of Acute Coronary events) risk scores still maintain their performance for predicting mortality in the era of contemporary management of acute coronary syndromes?

    American Heart Journal, Vol. 160, Núm. 5

2008

  1. Cooperative Cardiovascular Disease Research Network (RECAVA)

    Revista Espanola de Cardiologia, Vol. 61, Núm. 1, pp. 58-65

2000

  1. Incidence of haemorrhagic stroke in fibrinolytic treated patients after acute myocardial infarction. TIM study: A subgroup analysis

    Heart, Vol. 83, Núm. SUPPL. 2

  2. Randomized comparative trial of triflusal and aspirin following acute myocardial infarction

    European Heart Journal, Vol. 21, Núm. 6, pp. 457-465

  3. Triflusal vs aspirin in the acute phase of myocardial infarction: The TIM study main results

    Heart, Vol. 83, Núm. SUPPL. 2

1999

  1. Attenuated severity of new acute ischemic events in patients with previous coronary heart disease receiving long-acting nitrates

    Clinical Cardiology, Vol. 22, Núm. 4, pp. 303-308

  2. Incidence of vascular stroke in patients with acute myocardial infarction receiving fibrinolytic treatment

    European Heart Journal, Supplement

  3. Interaction between antiplatelet agents and ACE inhibitors in patients with acute myocardial infarction

    European Heart Journal, Supplement